Researchers used the methylCIBERSORT algorithm to determine the makeup of the tumor immune microenvironment of about 6,000 pediatric central nervous system tumors.
By screening more than 1,500 drugs against patient-derived glioblastoma cells, researchers tracked down tumor alterations with apparent ties to proteasome inhibitor response.
Investigators reported that methylation profiling could distinguish brain cancer subtypes and could detect kidney cancer with striking sensitivity in early experiments.
Presentations at the American Society of Clinical Oncology's virtual annual meeting included new findings relevant to both blood- and spinal fluid-based approaches.
A new microbiome analysis uncovered cancer type-specific bacterial community features, along with intracellular bacteria in tumor and associated immune cells.
